Inventurus Knowledge Solutions Limited IPO: Check IPO Date, Lot Size, Price & Details

About the company:

Established in 2006, Inventurus Knowledge Solutions Limited (IKS Health) specializes in providing administrative support services to healthcare organizations. The company streamlines processes for doctors and healthcare professionals by managing tasks like medical documentation, clinical support, and virtual scribing. With a focus on leveraging technology, IKS Health aims to enhance the efficiency of healthcare delivery while reducing the operational burden on providers. The company’s comprehensive platform caters to both outpatient and inpatient care settings. Outpatient services include diagnostic, treatment, and rehabilitation procedures that do not require hospital admission, while inpatient care involves medical treatment for patients staying overnight or longer in a healthcare facility. As of September 30, 2024, IKS Health supports over 778 healthcare providers, including prominent names like Mass General Brigham Inc., Texas Health Care PLLC, and The GI Alliance Management. The company’s workforce comprises more than 13,528 employees, with 2,612 clinically trained professionals, serving clients across the United States, Canada, and Australia.

IPO Details:

IPO Date

December 12, 2024 to December 16, 2024

Face Value

Rs. 1/- per share

Price Band

Rs. 1,265 to Rs. 1,329 per share

Lot Size

11 shares and in multiples thereof

Issue Size

Rs. 2,497.92 Crores

-          Offer for Sale - Rs. 2,497.92 Crores

Expected Post-Issue Market Cap

Rs. 22,802 Crores (At upper price band)

The objectives of the fresh issue:

The company will not receive any of the offer proceeds as the entire issue is an offer for sale and hence it will be received by the respective selling shareholders.

Key Strengths and Opportunities:

  • A key strength of Inventurus Knowledge Solutions Limited lies in its ability to provide a unified, end-to-end platform addressing the diverse needs of healthcare organizations across both outpatient and inpatient care. By offering a single, integrated solution, the company eliminates the complexities of managing multiple vendors, such as contract negotiations, IT integration, and compliance reviews. This streamlined approach not only reduces costs but also enhances accountability and efficiency throughout the patient care journey. By simplifying operations and enabling better outcomes, IKS Health positions itself as a valuable partner for healthcare providers seeking comprehensive and seamless support solutions.
  • Inventurus Knowledge Solutions Limited is recognized for its strong brand, built on clinical expertise and industry partnerships. Its reputation has been bolstered by the IKS Advisory Board, a leadership forum that fosters collaboration within the healthcare sector, as well as its alignment with respected organizations like the American Medical Group Association. The company’s presence across key markets in the US, Canada, and Australia is supported by a consultative sales approach, and its strategic marketing efforts have been amplified through positive client testimonials and referrals. Multiple awards and recognitions further highlight its standing in the healthcare industry.
  • Inventurus Knowledge Solutions Limited has established strong and enduring relationships with a diverse range of prestigious clients, including academic medical centers, healthcare systems, multi-specialty and single-specialty medical groups, and other outpatient care providers. This client base reflects the company’s ability to cater to complex healthcare needs across various segments. A significant indicator of its strength is the high level of client retention, with over 90% of revenues consistently generated from repeat clients in the past three fiscal years.

Risks:

  • Inventurus Knowledge Solutions Limited has faced certain compliance deficiencies in the past under FEMA regulations. These include issues related to the issuance and transfer of securities, as well as delays in meeting reporting requirements. The company, along with some of its current and former shareholders, has filed compounding applications with the Reserve Bank of India to address these contraventions, which are presently under review. As a result, there remains a risk of regulatory actions or penalties, including compounding fees, which could impact the company’s financial and operational standing.
  • The company may face risks if it is unable to effectively develop and integrate advanced technologies like artificial intelligence and machine learning into its offerings. The inability to introduce innovative solutions, such as AI-powered speech-to-text tools, or enhance existing services could negatively impact the company’s revenue growth, operational performance, and market reputation.
  • The ongoing challenges in the U.S. healthcare industry, such as the need to deliver high-quality care in a competitive market while controlling costs might have a negative impact on the company’s business operations. Additionally, the increasing trend of consolidation among healthcare organizations could pose risks to the company’s business operations, financial performance, and overall growth prospects. These industry dynamics may lead to shifts in client demands or changes in market structure, potentially affecting the company’s ability to sustain its current performance levels.

Financial Snapshot:

Particulars (Rs. in Millions)

6M Ended Sept 30, 2024

6M Ended Sept 30, 2023

FY24

FY23

FY22

Revenue from Operations

12,829

6,309

18,179

10,313

7,636

Y on Y Growth (%)

103%

 

76%

35%

 

Restated profit for the period

2,086

2,054

3,705

3,052

2,330

Y on Y Growth (%)

2%

 

21%

31%

 

EBITDA

3,591

2,322

5,203

3,604

2,774

Y on Y Growth (%)

55%

 

44%

30%

 

Cash Generated from Operations

2,856

2,491

3,030

3,630

2,772

Net Profit Margin (%)

16.26%

32.56%

20.38%

29.59%

30.51%

EBITDA Margin (%)

27.99%

36.81%

28.62%

34.95%

36.33%

Return on Equity (%)

15.15%

23.29%

32.00%

36.83%

36.00%

Conclusion:

Inventurus Knowledge Solutions Limited comes at an earnings valuation of 60x based on its earnings per share (EPS) as of March 31, 2024, and the upper price band. The company has no listed peer in India and hence, industry comparison is currently not possible. Considering the financials, risks, and future growth prospects, we advise our investors to consider subscribing to the Inventurus Knowledge Solutions IPO solely for potential listing gains.

Samco Fast Trading App

Download App to know your Andekha Sach

Get the link to download the app.

Leave A Comment?